Granted Patent
B2
US 12,545,705 · App. 19/177,248 · Granted Feb 10, 2026
IBAT inhibitors for the treatment of liver diseases
Inventors:
Per-Göran Gillberg (Åsbro, SE); Hans Graffner (Helsingborg, SE); Ingemar Starke (Gothenburg, SE)
Assignee:
Albireo AB
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Claims (2)
1 . A method for treating pruritus of cholestatic liver disease in a subject, the method comprising orally administering to a subject in need of such treatment a therapeutically effective amount an IBAT inhibitor, wherein the IBAT inhibitor is a hydrated form of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N—{(R)-α-[N—((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, wherein the cholestatic liver disease is Alagille syndrome (ALGS).
2 . A method for treating pruritus of cholestatic liver disease in a subject, the method comprising orally administering to a subject in need of such treatment a therapeutically effective amount an IBAT inhibitor, wherein the IBAT inhibitor is a hydrated form of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N—{(R)-α-[N—((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, wherein the cholestatic liver disease is progressive familial intrahepatic cholestasis (PFIC).
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 26, 2025
From: GILLBERG, PER-GÖRAN; GRAFFNER, HANS; STARKE, INGEMAR
To: ALBIREO AB
Reel/Frame 072121/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 26, 2025
From: GILLBERG, PER-GÖRAN; GRAFFNER, HANS; STARKE, INGEMAR
To: ALBIREO AB
Reel/Frame 072121/0726 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 11, 2025
From: GILLBERG, PER-GÖRAN; GRAFFNER, HANS; STARKE, INGEMAR
To: ALBIREO AB
Reel/Frame 070819/0233 →
Priority Claims (1)
SE 1051165-7
· Nov 8, 2010
· national
Continuity (8)
Continuation
13881447
Provisional Application
61410957
· Nov 8, 2010
References Cited (400)
US 3539380A
· Johnson
· 1970
[cited by applicant]
US 4507235A
· Wunsch
· 1985
[cited by applicant]
US 5167965A
· Schulz
· 1992
[cited by applicant]
US 5384130A
· Kamada
· 1995
[cited by applicant]
US 5663165A
· Brieaddy
· 1997
[cited by applicant]
US 5723458A
· Brieaddy et al.
· 1998
[cited by applicant]
US 5811388A
· Friend et al.
· 1998
[cited by applicant]
US 5817652A
· Brieaddy et al.
· 1998
[cited by applicant]
US 5900233A
· Day
· 1999
[cited by applicant]
US 5910494A
· Brieaddy
· 1999
[cited by applicant]
US 5976811A
· Mullner et al.
· 1999
[cited by applicant]
US 5994391A
· Lee et al.
· 1999
[cited by applicant]
US 5998400A
· Brieaddy et al.
· 1999
[cited by applicant]
US 6020330A
· Enhsen et al.
· 2000
[cited by applicant]
US 6069167A
· Sokol
· 2000
[cited by applicant]
US 6277831B1
· Frick et al.
· 2001
[cited by applicant]
US 6346527B1
· Takanaka et al.
· 2002
[cited by applicant]
US 6355672B1
· Yasuma et al.
· 2002
[cited by applicant]
US 6387924B2
· Lee et al.
· 2002
[cited by applicant]
US 6387944B1
· Frick et al.
· 2002
[cited by applicant]
US 6426340B1
· Gibson et al.
· 2002
[cited by applicant]
US 6562860B1
· Keller et al.
· 2003
[cited by applicant]
US 6635280B2
· Shell et al.
· 2003
[cited by applicant]
US 6642269B2
· Frick et al.
· 2003
[cited by applicant]
US 6676979B2
· Marlett et al.
· 2004
[cited by applicant]
US 6784201B2
· Lee et al.
· 2004
[cited by applicant]
US 6906058B2
· Starke et al.
· 2005
[cited by applicant]
US 6943189B2
· Keller et al.
· 2005
[cited by applicant]
US 7019023B2
· Frick et al.
· 2006
[cited by applicant]
US 7125864B2
· Starke et al.
· 2006
[cited by applicant]
US 7132416B2
· Starke et al.
· 2006
[cited by applicant]
US 7132557B2
· Wilkes et al.
· 2006
[cited by applicant]
US 7192945B2
· Starke et al.
· 2007
[cited by applicant]
US 7192946B2
· Starke et al.
· 2007
[cited by applicant]
US 7192947B2
· Starke et al.
· 2007
[cited by applicant]
US 7226943B2
· Starke et al.
· 2007
[cited by applicant]
US 7238684B2
· Starke et al.
· 2007
[cited by applicant]
US 7514421B2
· Abrahamsson et al.
· 2009
[cited by applicant]
US 7615536B2
· Frick et al.
· 2009
[cited by applicant]
US 7767229B1
· Milne et al.
· 2010
[cited by applicant]
US 7923468B2
· Frick et al.
· 2011
[cited by applicant]
US 7939061B2
· Prakash et al.
· 2011
[cited by applicant]
US 7956085B2
· Frick et al.
· 2011
[cited by applicant]
US 8048413B2
· Huguet
· 2011
[cited by applicant]
US 8067584B2
· Starke et al.
· 2011
[cited by applicant]
US 8101583B2
· Glombik et al.
· 2012
[cited by applicant]
US 8106023B2
· Glombik et al.
· 2012
[cited by applicant]
US 9295677B2
· Ling et al.
· 2016
[cited by applicant]
US 9339480B2
· Young et al.
· 2016
[cited by applicant]
US 9409875B2
· Bohlin et al.
· 2016
[cited by applicant]
US 9684018B2
· Horanzy
· 2017
[cited by applicant]
US 9688720B2
· Gillberg et al.
· 2017
[cited by applicant]
US 9694018B1
· Gillberg et al.
· 2017
[cited by applicant]
US 9701649B2
· Bohlin et al.
· 2017
[cited by applicant]
US 9745276B2
· Bohlin et al.
· 2017
[cited by applicant]
US 9872844B2
· Zernel et al.
· 2018
[cited by applicant]
US 20020142054A1
· Marlett et al.
· 2002
[cited by applicant]
US 20030125316A1
· Keller et al.
· 2003
[cited by applicant]
US 20030153541A1
· Dudley et al.
· 2003
[cited by applicant]
US 20030199515A1
· Mudipalli et al.
· 2003
[cited by applicant]
US 20040014806A1
· Bhat et al.
· 2004
[cited by applicant]
US 20040038862A1
· Goodwin et al.
· 2004
[cited by applicant]
US 20040062745A1
· Green et al.
· 2004
[cited by applicant]
US 20040077625A1
· Tremont et al.
· 2004
[cited by applicant]
US 20040082647A1
· Babiak et al.
· 2004
[cited by applicant]
US 20040176438A1
· Tremont et al.
· 2004
[cited by applicant]
US 20050124557A1
· Lindqvist
· 2005
[cited by applicant]
US 20050197376A1
· Kayakiri et al.
· 2005
[cited by applicant]
US 20050215882A1
· Chenevert et al.
· 2005
[cited by applicant]
US 20050287178A1
· Steed
· 2005
[cited by applicant]
US 20060083790A1
· Anderberg et al.
· 2006
[cited by applicant]
US 20070197522A1
· Edwards et al.
· 2007
[cited by applicant]
US 20080207592A1
· Frick et al.
· 2008
[cited by applicant]
US 20090131395A1
· Antonelli et al.
· 2009
[cited by applicant]
US 20100286122A1
· Belyk
· 2010
[cited by applicant]
US 20110152204A1
· Gedulin et al.
· 2011
[cited by applicant]
US 20110294767A1
· Gedulin et al.
· 2011
[cited by applicant]
US 20120114588A1
· Starke et al.
· 2012
[cited by applicant]
US 20120157399A1
· Young et al.
· 2012
[cited by applicant]
US 20130108573A1
· Gedulin et al.
· 2013
[cited by applicant]
US 20130109671A1
· Gedulin et al.
· 2013
[cited by applicant]
US 20130225511A1
· Gillberg et al.
· 2013
[cited by applicant]
US 20130236541A1
· Gillberg et al.
· 2013
[cited by applicant]
US 20140275090A1
· Gedulin et al.
· 2014
[cited by applicant]
US 20150031636A1
· Gillberg et al.
· 2015
[cited by applicant]
US 20150031637A1
· Gillberg et al.
· 2015
[cited by applicant]
US 20170143738A1
· Ando et al.
· 2017
[cited by applicant]
US 20170182059A1
· Gillberg et al.
· 2017
[cited by applicant]
US 20170182115A1
· Gillberg et al.
· 2017
[cited by applicant]
US 20190276493A1
· Bhat et al.
· 2019
[cited by applicant]
US 20200330545A1
· Gillberg et al.
· 2020
[cited by applicant]
US 20210171479A1
· Gillberg
· 2021
[cited by applicant]
US 20230049950A1
· Gillberg et al.
· 2023
[cited by applicant]
US 20230330176A1
· Gillberg et al.
· 2023
[cited by applicant]
US 20230338392A1
· Lindström et al.
· 2023
[cited by applicant]
US 20230398125A1
· Lindström et al.
· 2023
[cited by applicant]
US 20240067617A1
· Starke et al.
· 2024
[cited by applicant]
US 20240130976A1
· Byrod et al.
· 2024
[cited by applicant]
US 20240173333A1
· Mattsson et al.
· 2024
[cited by applicant]
US 20240207286A1
· Lindström et al.
· 2024
[cited by applicant]
US 20250019353A1
· Gillberg et al.
· 2025
[cited by applicant]
US 20250019354A1
· Lundqvist et al.
· 2025
[cited by applicant]
US 20250100983A1
· Gillberg et al.
· 2025
[cited by applicant]
DE 3930168A1
· 1991
[cited by applicant]
DE 19825804C2
· 2000
[cited by applicant]
EP 0278464A1
· 1988
[cited by applicant]
EP 0489423A1
· 1991
[cited by applicant]
EP 0372542B1
· 1992
[cited by applicant]
EP 0573848A2
· 1993
[cited by applicant]
EP 0549967A1
· 1993
[cited by applicant]
EP 0624593A2
· 1994
[cited by applicant]
EP 0624594A2
· 1994
[cited by applicant]
EP 0624595A2
· 1994
[cited by applicant]
EP 0624596A2
· 1994
[cited by applicant]
EP 0864582A2
· 1998
[cited by applicant]
EP 1173205A1
· 2000
[cited by applicant]
EP 1535913A1
· 2005
[cited by applicant]
EP 1719768A1
· 2006
[cited by applicant]
EP 2144599A2
· 2010
[cited by applicant]
EP 3210977A2
· 2017
[cited by applicant]
GB 1573487A
· 1980
[cited by applicant]
GB 2262888B
· 1996
[cited by applicant]
JP 2000513028A
· 2000
[cited by applicant]
JP 2004516285A
· 2004
[cited by applicant]
JP 3665055B2
· 2005
[cited by applicant]
JP 4870552B2
· 2012
[cited by applicant]
JP 2013541584A
· 2013
[cited by applicant]
JP 2013542953A
· 2013
[cited by applicant]
JP 5421326B2
· 2014
[cited by applicant]
JP H02258719A
· 2019
[cited by applicant]
WO WO199103249A1
· 1991
[cited by applicant]
WO WO199316055A1
· 1993
[cited by applicant]
WO WO199400111A1
· 1994
[cited by applicant]
WO WO199418183A1
· 1994
[cited by applicant]
WO WO199418184A1
· 1994
[cited by applicant]
WO WO199605188A1
· 1996
[cited by applicant]
WO WO199608484A1
· 1996
[cited by applicant]
WO WO199616051A1
· 1996
[cited by applicant]
WO WO199733882A1
· 1997
[cited by applicant]
WO WO199803818A1
· 1998
[cited by applicant]
WO WO199807449A2
· 1998
[cited by applicant]
WO WO199838182A1
· 1998
[cited by applicant]
WO WO199840375A2
· 1998
[cited by applicant]
WO WO199856757A1
· 1998
[cited by applicant]
WO WO199901149A1
· 1999
[cited by applicant]
WO WO199932478A1
· 1999
[cited by applicant]
WO WO199935135A1
· 1999
[cited by applicant]
WO WO199964409A2
· 1999
[cited by applicant]
WO WO199964410A1
· 1999
[cited by applicant]
WO WO200001687A1
· 2000
[cited by applicant]
WO WO200038725A1
· 2000
[cited by applicant]
WO WO200038726A1
· 2000
[cited by applicant]
WO WO200038727A1
· 2000
[cited by applicant]
WO WO200038728A1
· 2000
[cited by applicant]
WO WO200038729A1
· 2000
[cited by applicant]
WO WO200047568A2
· 2000
[cited by applicant]
WO WO200061568A2
· 2000
[cited by applicant]
WO WO200062810A1
· 2000
[cited by applicant]
WO WO200134570A1
· 2001
[cited by applicant]
WO WO200160807A1
· 2001
[cited by applicant]
WO WO200166533A1
· 2001
[cited by applicant]
WO WO200168096A2
· 2001
[cited by applicant]
WO WO200168637A2
· 2001
[cited by applicant]
WO WO200208211A2
· 2002
[cited by applicant]
WO WO200232428A1
· 2002
[cited by applicant]
WO WO200250051A1
· 2002
[cited by applicant]
WO WO200253548A1
· 2002
[cited by applicant]
WO WO2003020710A1
· 2003
[cited by applicant]
WO WO2003022286A1
· 2003
[cited by applicant]
WO WO2003022804A2
· 2003
[cited by applicant]
WO WO2003022825A1
· 2003
[cited by applicant]
WO WO2003022830A1
· 2003
[cited by applicant]
WO WO2003043992A1
· 2003
[cited by applicant]
WO WO2003051821A1
· 2003
[cited by applicant]
WO WO2003051822A1
· 2003
[cited by applicant]
WO WO2003061663A1
· 2003
[cited by applicant]
WO WO2003091232A2
· 2003
[cited by applicant]
WO WO2003106482A1
· 2003
[cited by applicant]
WO WO2004006899A1
· 2004
[cited by applicant]
WO WO2004020421A1
· 2004
[cited by applicant]
WO WO2004056748A1
· 2004
[cited by applicant]
WO WO2004076430A1
· 2004
[cited by applicant]
WO WO2004089350A1
· 2004
[cited by applicant]
WO WO2005082874A1
· 2005
[cited by applicant]
WO WO2007009655A1
· 2007
[cited by applicant]
WO WO2007009656A2
· 2007
[cited by applicant]
WO WO2008058628A1
· 2008
[cited by applicant]
WO WO2008058630A1
· 2008
[cited by applicant]
WO WO2008058631A1
· 2008
[cited by applicant]
WO WO2010041268A2
· 2010
[cited by applicant]
WO WO2010062861A2
· 2010
[cited by applicant]
WO WO2010106249A1
· 2010
[cited by applicant]
WO WO2011137135A1
· 2011
[cited by applicant]
WO WO2011150286A2
· 2011
[cited by applicant]
WO WO2012064266A1
· 2012
[cited by applicant]
WO WO2012064267A1
· 2012
[cited by applicant]
WO WO2012064268A1
· 2012
[cited by applicant]
WO WO2013063512A1
· 2013
[cited by applicant]
WO WO2013063526A1
· 2013
[cited by applicant]
WO WO2013168671A1
· 2013
[cited by applicant]
WO WO2014174066A1
· 2014
[cited by applicant]
WO WO2016062848A1
· 2016
[cited by applicant]
WO WO2017138876A1
· 2017
[cited by applicant]
WO WO2017138877A1
· 2017
[cited by applicant]
WO WO2017138878A1
· 2017
[cited by applicant]
WO WO2019017724A1
· 2019
[cited by applicant]
WO WO2019032026A1
· 2019
[cited by applicant]
WO WO2019032027A1
· 2019
[cited by applicant]
WO WO2019172834A1
· 2019
[cited by applicant]
WO WO2019234077A1
· 2019
[cited by applicant]
WO WO2019245448A1
· 2019
[cited by applicant]
WO WO2019245449A1
· 2019
[cited by applicant]
WO WO2020194531A1
· 2020
[cited by applicant]
WO WO2020161216A1
· 2020
[cited by applicant]
WO WO2020161217A1
· 2020
[cited by applicant]
WO WO2020167958A1
· 2020
[cited by applicant]
WO WO2020167964A1
· 2020
[cited by applicant]
WO WO2020167981A1
· 2020
[cited by applicant]
WO WO2020167985A1
· 2020
[cited by applicant]
WO WO2021110883A1
· 2021
[cited by applicant]
WO WO2021110884A1
· 2021
[cited by applicant]
WO WO2021110885A1
· 2021
[cited by applicant]
WO WO2021110886A1
· 2021
[cited by applicant]
WO WO2021110887A1
· 2021
[cited by applicant]
WO WO2022029101A1
· 2022
[cited by applicant]
WO WO2022101379A1
· 2022
[cited by applicant]
WO WO2022117778A1
· 2022
[cited by applicant]
WO WO2022253997A1
· 2022
[cited by applicant]
WO WO2023203248A1
· 2023
[cited by applicant]
WO WO2024008766A1
· 2024
[cited by applicant]
[No Author Listed], “Practical Pharmaceutical Preparation Technology,” People's Medical Publishing House, Jan. 1999, 286-287 (Machine Translation).
[cited by applicant]
AccessData.FDA.gov [online], “Livmarli® (maralixibat) oral solution, Initial U.S. Approval: 2021,” FDA Drug Label (Reference ID: 5345945), last revised on Mar. 2024, 30 pages.
[cited by applicant]
Adams et al., “Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection,” Clin. Chem., 2005, 51(10):1867-1873.
[cited by applicant]
Alashkar et al., “Persisting Hyperbilirubinemia in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Chronically Treated with Eculizumab: The Role of Hepatocanalicular Transport Variants,” Abstract, Presented at P…
[cited by applicant]
AlbireoPharma.com [online], “Initiation of a Phase II Trial for A4250, the Company's Lead Compound for Cholestatic Liver Diseases and NASH,” Albireo Pharma Press Release, Feb. 5, 2015, retrieved from URL<http://www.albi…
[cited by applicant]
Albireo's Lead Compound in Cholestatic Liver Diseases, A4250, Projects Against Bile Acid-Mediated Cholestatic Liver Injury in Mice, Albireo Press Release, Apr. 11, 2014, 2 pages.
[cited by applicant]
Al-Dury, “Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH,” Frontiers in Pharmacology, 2018, 9:931.
[cited by applicant]
Alissa et al., “Invited Review: Update on Progressive Familial Intrahepatic Cholestasis,” Journal of Pediatric Gastroenterology and Nutrition, 2008, 46:241-252.
[cited by applicant]
Almasio et al., “Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis,” Drugs, 1990, 40 Suppl (3):111-123.
[cited by applicant]
Alnouti, “Bile acid sulfation: a pathway of bile acid elimination and detoxification,” Toxicological Sciences, 2009, 108(2):225-246.
[cited by applicant]
Alonso et al., “Histologic pathology of the liver in progressive familial intrahepatic cholestasis,” Journal of Pediatric Gastroenterology and Nutrition, 14:128-133, 1994.
[cited by applicant]
Alvarez et al., “Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1,” Hum. Mol. Genet., 2004, 13(20):2451-2460.
[cited by applicant]
Alvarez, “Development of crystallization processes for pharmaceutical applications,” LACCEI, 2007, 2E.3-1-2E.3-9.
[cited by applicant]
Alvarez, “Treatments in chronic cholestasis in children.” Ann. Nestlé, 2008, 66:127-135.
[cited by applicant]
American Diabetes Association, “Management of Dyslipidemia in Adults with Diabetes, ” Diabetes Care, Jan. 2003, 26(1).
[cited by applicant]
Anakk et al., “Bile acids activate YAP to promote liver carcinogenesis,” Cell Rep., Nov. 27, 2013, 5(4):1060-1069.
[cited by applicant]
Angulo et al., “Independent Predictors of Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis,” Hepatology, Dec. 1999, 30(6): 1356-1362.
[cited by applicant]
Angulo et al., “The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD,” Hepatology, 2007, 45(4):846-854.
[cited by applicant]
Angulo, “Use of ursodeoxycholic acid in patients with liver disease,” Current Gastroenterology Reports, Feb. 2002, 4(1):37-44.
[cited by applicant]
Anzivino et al., “ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population,” Dig. Liver Dis., 2013, 45(3):226-232.
[cited by applicant]
Appleby et al., “Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea,” Un…
[cited by applicant]
Arnell et al., “Follow-up in children with progressive familial intrahepatic cholestasis after partial external biliary diversion,” J. Pediatr. Gastroenterol. Nutr., 2010, 51(4):494-499.
[cited by applicant]
Artursson et al., “Correlation Between Oral Drug Absorption in Humans and Apparent Drug Permeability Coefficients in Human Intestinal Epithelial (CACO-2) Cells,” Biochemical and Biophysical Research Communications, Mar.…
[cited by applicant]
Asami et al., “Treatment of children with familial hypercholesterolemia with colestilan, a newly developed bile acid-binding resin,” Atherosclerosis, 2002, 164:381-2.
[cited by applicant]
Attili et al., “Bile Acid-induced Liver Toxicity: Relation to the Hydrophobic- Hydrophilic Balance of Bile Acids, ” Medical Hypotheses, 1986, 19:57-69.
[cited by applicant]
Baghdasaryan et al., “Inhibition of intestinal bile acid absorption by ASBT inhibition A4250 protects against bile acid-mediated cholestatic liver injury in mice,” J. Hepatology, 2014, 60:S57.
[cited by applicant]
Bajor et al., “Bile acids: short and long term effects in the intestine,” Scandinavian J. Gastro., 2010, 45:645-664.
[cited by applicant]
Baker et al. “Systematic review of progressive familial intrahepatic cholestasis,” Clin. Res. Hepatol. Gastroenterol., 2019;43:20-36.
[cited by applicant]
Balbach et al., “Pharmaceutical evaluation of early development candidates ‘the 100 mg-approach’,” Int. J. Pharm., May 4, 2004, 275(1):1-12.
[cited by applicant]
Banker et al., “Modern Pharmaceutics,” 3rd edition, Marcel Dekker, New York, 1996, pp. 451 and 596.
[cited by applicant]
Baringhaus, “Substrate specificity of the ileal and the hepatic Na+/bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na+/bile acid cotransporter,” J. Lipid Res., 1999, 40:…
[cited by applicant]
Bass et al., “Inherited Disorders of Cholestasis in Adulthood,” Clin. Liver. Dis., 2013, 2(5):200-203.
[cited by applicant]
Bastin et al., “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities,” Org. Process Res. Dev., 2000, 4:427-435.
[cited by applicant]
Baumann et al., “Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study,” Clin. Res. Hepatol. Gastroenterol., Sep. 2021, 45(5):101751.
[cited by applicant]
Baumann et al., “The ileal bile acid transport inhibitor A4250 decreases pruritus and serum bile acids in cholestatic liver diseases—an ongoing multiple dose, open-label, multicenter study,” Hepatology, 2017, 66(1): S91…
[cited by applicant]
Bavin, “Polymorphism in Process Development,” Chemistry and Industry, 527-529, 1989.
[cited by applicant]
Beausejour et al., “Description of two new ABCB11 mutations responsible for type 2 benign recurrent intrahepatic cholestasis in a French-Canadian family,” Can. J. Gastroenterol., 2011, 25(6):311-314.
[cited by applicant]
Belikov, “[The relationship between the chemical structure, properties of substances and their effect on the body], ” Pharmacevticheskaja khimija, Moskva, “MEDpress-inform,” 2007, Chapter 2.5-2.7, pp. 27-29, 5 pages (wi…
[cited by applicant]
Beraza et al., “Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis,” Gut, 2011, 60: 387-396.
[cited by applicant]
Bernstein et al., “Bile acids as endogenous etiologic agents in gastrointestinal cancer,” World J. Gastroenterol., Jul. 2009, 15(27):3329-3340.
[cited by applicant]
Billington et al., “Effects of bile salts on the plasma membranes of isolated rat hepatocytes,” Biochem. J. 188: 321-327, 1980.
[cited by applicant]
Blackmore et al., “Polymorphisms in ABCB11 and ATP8B1 Associated with Development of Severe Intrahepatic Cholestasis in Hodgkin's Lymphoma,” J. Clin. Exp. Hepatol., 2013, 3(2):159-161.
[cited by applicant]
Blank et al., “The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics,” Clin. Pharmacol. Ther., Feb. 2018, 103(2):341-348.
[cited by applicant]
Board of Appeal of European Patent Office, Case No. T 077/08-3.3.01, Datasheet for the decision of May 24, 2011, 17 pages.
[cited by applicant]
Boncristani et al., “Respiratory Viruses,” Encyclopedia of Microbiology, 2009, 19 pages.
[cited by applicant]
Bonge et al., “Cytostar-T Scintillating Microplate Assay for Measurement of Sodium-Dependent Bile Acid Uptake in Transfected HEK-293 Cells,” Analytical Biochemistry, 2000, 282:94-101.
[cited by applicant]
Bonn et al., “SAT380—The orally available sodium/taurocholate co-transporting polypeptide inhibitor A2342 blocks hepatitis B and D entry in vitro,” Poster, Presented at the European Association for the Study of the Live…
[cited by applicant]
Bounford, “Investigations into the genetic causes of liver disease using molecular genetic technologies,” Thesis for the degree of Doctor of Philosophy, University of Birmingham, School of Clinical and Experimental Medi…
[cited by applicant]
Bowel Diversion Surgeries: Ileostomy, Colostomy, Ileoanal Reservoir and Continent Ileostomy, US Department of Health and Human Services: National Institute of Diabetes and Digestive And Kidney Diseases, Feb. 2009, retri…
[cited by applicant]
Braadland et al., “Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis,” JHEP Rep., Aug. 2022, 4(11):100561.
[cited by applicant]
Braga et al., “Crystal Polymorphism and Multiple Crystal Forms,” Struct. Bond., Feb. 2009, 132:25-50.
[cited by applicant]
Brunt et al., “Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging the Histological Lesions,” American Journal of Gastroenterology, Sep. 1999, 94(9): 2467-2474.
[cited by applicant]
Brunzell et al., “Dyslipidemia of Central Obesity and Insulin Resistance,” Diabetes Care, 1999, 22(Suppl. 3):C10-C13.
[cited by applicant]
Bull et al., “Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity,” Hepatology, 26: 1, 155-164, 1997.
[cited by applicant]
Bull et al., “Progressive Familial Intrahepatic Cholestasis,” Clin. Liver Dis., Nov. 2018, 22:4:657-669.
[cited by applicant]
Burrows, “Interventions for treating cholestasis in pregnancy,” Cochrane Database Syst. Rev., 4:CD00493, 2001.
[cited by applicant]
Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 1995, 12(7):945-954.
[cited by applicant]
Byrne et al., “Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing,” Hepatology, 2009, 49(2):553-567.
[cited by applicant]
Caira, “Crystalline Polymorphism of Organic Compounds,” in: Topics in Current Chemistry, Jan. 1998, 198:163-208.
[cited by applicant]
Camilleri, “Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy,” Clin. Gastroenterol., 40(3):264-9, Mar. 2006.
[cited by applicant]
Case-Lo, “What Is a Subcutaneous Injection?” Healthline.com [online], Sep. 2018, retrieved on Oct. 7, 2022, retrieved from URL<https://www.healthline.com/health/subcutaneous-injection>, 25 pages.
[cited by applicant]
Centeno, “Molecular mechanisms triggered by low-calcium diets,” Nutrition Research Reviews., 22(2):163-74, Dec. 2009.
[cited by applicant]
Chalasani et al., “The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases,” Hepatology, 2018, 67(1):328-357.
[cited by applicant]
Chang et al., “Bile acids promote the expression of hepatitis C virus in replicon-harboring cells,” Journal of Virology, Sep. 2007, 81(18):9633-9640.
[cited by applicant]
Charach et al., “The association of bile acid excretion and atherosclerotic coronary artery disease,” Therapeutic Advances in Gastroenterology, 2011, 4(2):95-101.
[cited by applicant]
Chauhan et al., “Pharmaceutical polymers,” Encycl. Biomed. Polymers and Polymeric Biomaterials, 2016, 5929-5942.
[cited by applicant]